Prostanoids for the management of glaucoma.
BACKGROUND
Prostanoids are the newest pharmacologic group of ocular hypotensive drugs for clinical management of glaucoma. The group includes four chemical compounds structurally derived from naturally-occurring prostaglandin (PG) F(2). Prostanoids have been divided into PG analogues (unoprostone, latanoprost and travoprost) and prostamides (bimatoprost) because of differences in molecular structures. The drugs share a novel mechanism of action that produces a potent ocular hypotensive effect and a novel local adverse effect of increased iridial pigmentation.


OBJECTIVE
To summarise the pharmacologic and clinical data regarding the effectiveness and safety of prostanoids in clinical glaucoma management.


METHODS
The review was supported by a literature search of peer-reviewed publications, based on medical information available in databases such as PubMed.


CONCLUSIONS
The prostanoids began a treatment revolution not only because of their novel mechanism of action but also as a result of a new local side effect.
Arranz-Marquez
Esther
E
Vissum Madrid C/Santa Hortensia 58, 28002, Madrid, Spain. e.arranzmarquez@gmail.com
Teus
Miguel A
MA
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005127:Eye Color / Q000187:drug effects; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007498:Iris / Q000187:drug effects / Q000378:metabolism; D009798:Ocular Hypertension / Q000188:drug therapy; D010858:Pigmentation / Q000187:drug effects; D011453:Prostaglandins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D011453:Prostaglandins